Impact of glycemic variability on early detection of sudomotor dysfunction: Implications for early intervention and
Yang Ou1, Xiao-Feng Hu2, Zhi Liang3
1Department of Endocrinology and Metabolism, First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, China.
Background:
This study investigates the impact of glycemic variability on sudomotor dysfunction in type 2 diabetes mellitus.
Methods:
A total of 206 type 2 diabetes mellitus patients and 34 healthy controls were included. Sweat function (SF) was assessed using electrochemical conductance of hands (HESC) and feet (FESC). Type 2 diabetes mellitus patients underwent continuous glucose monitoring (CGM), and blood glucose variability was analyzed using various metrics. Type 2 diabetes mellitus patients were classified into normal, abnormal, reversible, and persistent abnormal SF groups.
Results:
In healthy controls, SF showed no circadian rhythm. Type 2 diabetes mellitus patients with abnormal SF had longer diabetes duration, higher glucose variability, and greater SF impairment (P < 0.05). The reversible group exhibited the largest SF fluctuations (~26 μS) and a significant correlation between glucose variability and SF (P < 0.05). Blood glucose levels of 5-10 mmol/L were associated with improved SF in this group.
Conclusions:
The findings suggest that greater glucose variability correlates with more severe peripheral nerve damage, and controlling blood glucose within 5-10 mmol/L may improve SF, offering insights for personalized treatment strategies in diabetic peripheral neuropathy (DPN) prevention.
More Related Videos
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia and Glucagon
